Marrone Bio Innovations, Inc. provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation. The company's products include Regalia, a plant extract-based fungicidal biopesticide for plant disease control and plant health; and Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants. It also provides Zequanox, a biomolluscicide that controls invasive mussels, which cause infrastructure and ecological damage primarily to power and industrial companies; and Venerate, a bioinsecticide, which controls chewing and sucking insects and mites, as well as flies and plant parasitic nematodes. In addition, the company offers Haven, an sun protectant product that reduces plant stress and dehydration; and Majestene and Zelto, a bionematicide to control soil-dwelling nematodes by preventing and reducing root galls, as well as reducing adult reproduction and egg hatch. Further, it provides Stargus and Amplitude, a biofungicide for improving plant health. Marrone Bio Innovations, Inc. provides its products directly through sales force, as well as through distributors. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was founded in 2006 and is headquartered in Davis, California.
Industry, Sector and Symbol
Industry Agricultural chemicals
Sub-IndustryN/A
SectorBasic Materials
Phone530-750-2800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.17 million
Profitability
Miscellaneous
Employees103
Next Earnings Date4/4/2019 (Estimated)
OptionableNot Optionable
Marrone Bio Innovations (NASDAQ:MBII) Frequently Asked Questions
What is Marrone Bio Innovations' stock symbol?
Marrone Bio Innovations trades on the NASDAQ under the ticker symbol "MBII."
How were Marrone Bio Innovations' earnings last quarter?
Marrone Bio Innovations Inc (NASDAQ:MBII) posted its quarterly earnings results on Tuesday, August, 14th. The basic materials company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. The basic materials company earned $5.75 million during the quarter, compared to the consensus estimate of $7.01 million. Marrone Bio Innovations had a negative return on equity of 2,570.84% and a negative net margin of 105.87%. View Marrone Bio Innovations' Earnings History.
When is Marrone Bio Innovations' next earnings date?
What price target have analysts set for MBII?
3 equities research analysts have issued 12 month price targets for Marrone Bio Innovations' shares. Their predictions range from $1.55 to $3.00. On average, they anticipate Marrone Bio Innovations' share price to reach $2.35 in the next year. This suggests a possible upside of 46.9% from the stock's current price. View Analyst Price Targets for Marrone Bio Innovations.
What is the consensus analysts' recommendation for Marrone Bio Innovations?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marrone Bio Innovations in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Marrone Bio Innovations.
What are Wall Street analysts saying about Marrone Bio Innovations stock?
Here are some recent quotes from research analysts about Marrone Bio Innovations stock:
- 1. National Securities analysts commented, "▪ Growth Set To Accelerate – Macro tailwinds and internal developments are aligning such that we believe growth will make a meaningful step up in 2019 and into 2020. The nearly 30% revenue growth seen in the third quarter of 2018 represents what we believe to be the beginning of a trend, as we are modeling revenue to double from 2018 to 2020.
▪ Seed Treatment Business A Significant Near-Term Driver – A distribution agreement with Albaugh is ramping towards an expected $8 to $10 million run rate in 2020, representing the largest driver of growth over the next two years. Efforts are underway to expand the business beyond these levels, and we believe there is a meaningful opportunity both with additional microbes at Albaugh or with additional distributors.
▪ Cannabis Applications Taking Off – Venerate’s approval for cannabis grown in California last week represents the latest in a string of approvals in key states over the past year. While adoption of any inputs takes time after approval is granted, we anticipate cannabis being one of the key growth drivers in both the near and long term.
▪ Broad Product Suite Coming Online At The Right Time – With several products launching recently, MBII is expanding its offerings while the agriculture industry is becoming increasingly aware of the potential for biologicals. As such, we expect revenue growth to come from both an expanding market and an increase in market share.
▪ Positioning And Growth Outlook Unique Within Agriculture Industry – We believe MBII possesses one of the most compelling positions of small cap investments within the agriculture industry given its pure play focus on the high growth biological space." (2/14/2019)
- 2. According to Zacks Investment Research, "Marrone Bio Innovations Inc. develops environmentally safe bio-based products. The Company specializes in the discovery, development, and marketing of natural products for weed, pest, water resource, and plant disease management. It offers crop protection products for conventional and organic crop production, including herbicides for weed control, fungicides for plant disease control, nematicides for parasitic roundworm control, insecticides for insect and mite killers and plant growth regulators that growers use to increase crop yields, enhance plant health, manage pest resistance, and reduce chemical residues. Marrone Bio Innovations Inc. is headquartered in Davis, California. " (11/29/2018)
- 3. HC Wainwright analysts commented, "We are lowering our price target on MBII to $2.50, from $3.50 previously, driven by: (1) effect of salesforce attrition, experienced earlier in 2018, that has continued to negatively impact the pace of topline revenue growth; (2) slower than expected regulatory approval process for the company’s bioinsecticides, biofubgicides, and biopesticides.; and (3) longer than expected sales cycles. We are now taking a slightly more conservative stance on our forward projections for MBII, resulting in the lowered price target. Please see the valuation section of this note for more details. 3Q18 results overview. 2018, MBII reported revenues of $5.4M for the quarter (28.6% YoY increase). Gross margins were 48.3% for the quarter, compared to 40.9% in the year ago period." (11/14/2018)
Has Marrone Bio Innovations been receiving favorable news coverage?
News headlines about MBII stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Marrone Bio Innovations earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned press coverage about the basic materials company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Who are some of Marrone Bio Innovations' key competitors?
Some companies that are related to Marrone Bio Innovations include American Vanguard (AVD), Calyxt (CLXT), CVR Partners (UAN), Evogene (EVGN), Arcadia Biosciences (RKDA), SenesTech (SNES), China Green Agriculture (CGA), Bion Environmental Technologies (BNET), Kiwa Bio-Tech Products Group (KWBT), Cavitation Technologies (CVAT), Eden Research (EDEN), Monsanto (MON), Syngenta (SYT), Terra Nitrogen (TNH) and Wynnstay Group (WYN).
What other stocks do shareholders of Marrone Bio Innovations own?
Who are Marrone Bio Innovations' key executives?
Marrone Bio Innovations' management team includes the folowing people:
- Dr. Pamela G. Marrone, Founder, CEO & Director (Age 62)
- Mr. James B. Boyd, Pres & CFO (Age 66)
- Ms. Linda V. Moore, Chief Compliance Officer, Gen. Counsel, Exec. VP & Sec. (Age 72)
- Dr. Amit Vasavada Ph.D., Sr. VP of R&D and CTO (Age 64)
- Mr. Brian R. Ahrens, VP of Sales & Bus. Devel. (Age 48)
Who are Marrone Bio Innovations' major shareholders?
Marrone Bio Innovations' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.53%), Geode Capital Management LLC (0.40%), Rhumbline Advisers (0.06%) and Paloma Partners Management Co (0.04%). Company insiders that own Marrone Bio Innovations stock include Ardsley Advisory Partners, Van Herk Investments BV and Waddell & Reed Financial Inc. View Institutional Ownership Trends for Marrone Bio Innovations.
Which major investors are buying Marrone Bio Innovations stock?
MBII stock was bought by a variety of institutional investors in the last quarter, including Paloma Partners Management Co, Geode Capital Management LLC, Rhumbline Advisers and BlackRock Inc.. Company insiders that have bought Marrone Bio Innovations stock in the last two years include Ardsley Advisory Partners, Van Herk Investments BV and Waddell & Reed Financial Inc. View Insider Buying and Selling for Marrone Bio Innovations.
How do I buy shares of Marrone Bio Innovations?
Shares of MBII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Marrone Bio Innovations' stock price today?
One share of MBII stock can currently be purchased for approximately $1.60.
How big of a company is Marrone Bio Innovations?
Marrone Bio Innovations has a market capitalization of $177.10 million and generates $18.17 million in revenue each year. The basic materials company earns $-30,920,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Marrone Bio Innovations employs 103 workers across the globe.
What is Marrone Bio Innovations' official website?
How can I contact Marrone Bio Innovations?
Marrone Bio Innovations' mailing address is 1540 Drew Avenue, Davis CA, 95618. The basic materials company can be reached via phone at 530-750-2800 or via email at [email protected]
MarketBeat Community Rating for Marrone Bio Innovations (NASDAQ MBII)
MarketBeat's community ratings are surveys of what our community members think about Marrone Bio Innovations and other stocks. Vote "Outperform" if you believe MBII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBII will underperform the S&P 500 over the long term. You may vote once every thirty days.
